Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus

被引:25
作者
Briani, C
Zara, G
Rondinone, R
Iaccarino, L
Ruggero, S
Toffanin, E
Ermani, M
Ghirardello, A
Zampieri, S
Sarzi-Puttini, P
Doria, A
机构
[1] Univ Padua, Dept Neurosci, I-35128 Padua, Italy
[2] Univ Padua, Dept Med & Surg Sci, Div Rheumatol, Padua, Italy
[3] Univ Hosp L Sacco, Dept Internal Med, Rheumatol Unit, Milan, Italy
关键词
thalidomide; lupus erythematosus; peripheral neuropathy; neurotoxicity;
D O I
10.1080/08916930500285790
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Thalidomide is used in cutaneous lupus erythematosus (CLE) refractory to conventional therapies. Peripheral neuropathy (PN) is the most severe side effect, but the incidence of PN and its relation to thalidomide dose are still unclear. Objective: To prospectively evaluate the efficacy as well as the occurrence of PN in CLE patients treated with thalidomide, and to assess whether PN, when occurs, correlates with thalidomide dose and/or length of treatment. Methods: Fourteen female patients with CLE in low-dose thalidomide therapy were followed for up to 24 months. Prior to, and regularly during treatment patients underwent rheumatological, dermatological, neurological and electrophysiological evaluations. A decline in sural SNAP of 50% or more from baseline value was considered as criterion of sensory axonal PN. Results: All patients showed a dramatic improvement of skin manifestations. Ten patients (71.4%) developed a sensory axonal PN. The median time free from this complication was 14 months. No correlations were found between age of the patients nor thalidomide cumulative dose and occurrence of PN (Mann-Whitney U Test; p > 0.16). Other adverse effects were: tremor, paresthesias, somnolence, amenhorrea, constipation and thoracic pain. Conclusions: Low does thalidomide is efficacious in treating CLE, but PN is a common complication whose occurrence does not seem to correlate with total thalidomide dose, whereas with the duration of therapy. A closer electrophysiological follow-up is therefore recommended in the long-term treatment.
引用
收藏
页码:549 / 555
页数:7
相关论文
共 34 条
[11]   THALIDOMIDE NEUROPATHY - A CLINICAL ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FOLLOW-UP STUDY [J].
FULLERTON, PM ;
OSULLIVA.DJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1968, 31 (06) :543-+
[12]   CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY [J].
GARDNERMEDWIN, JMM ;
SMITH, NJ ;
POWELL, RJ .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (12) :828-832
[13]  
GHIRARDELLO A, 1994, ANN RHEUM DIS, V53, P40
[14]   Thalidomide-induced neuropathy: a ganglionopathy? [J].
Giannini, F ;
Volpi, N ;
Rossi, S ;
Passero, S ;
Fimiani, M ;
Cerase, A .
NEUROLOGY, 2003, 60 (05) :877-878
[15]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[16]   p75-mediated NF-κB activation enhances the survival response of developing sensory neurons to nerve growth factor [J].
Hamanoue, M ;
Middleton, G ;
Wyatt, S ;
Jaffray, E ;
Hay, RT ;
Davies, AM .
MOLECULAR AND CELLULAR NEUROSCIENCE, 1999, 14 (01) :28-40
[17]  
HARLAND CC, 1995, EUR J CLIN PHARMACOL, V49, P1
[18]  
HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x
[19]   THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION [J].
HESS, CW ;
HUNZIKER, T ;
KUPFER, A ;
LUDIN, HP .
JOURNAL OF NEUROLOGY, 1986, 233 (02) :83-89
[20]   Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus [J].
Housman, TS ;
Jorizzo, JL ;
McCarty, MA ;
Grummer, SE ;
Fleischer, AB ;
Sutej, PG .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :50-54